BioMark Diagnostics IncCanadian Securities Exchange:BUXView on OTC Pink - Current Information
- LAST PRICE0.1800
- TODAY'S CHANGE (%)-0.0400 (-18.1818%)
- Bid / Lots0.1800/ 8
- Ask / Lots0.2000/ 1
- Open / Previous Close0.2200 / 0.2200
- Day Range
- 52 Week Range
- Volume94,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BUX |
|---|---|---|
| 02:09 ET | 62000 | 0.18 |
| 02:16 ET | 9500 | 0.18 |
| 02:34 ET | 500 | 0.2 |
| 02:38 ET | 500 | 0.2 |
| 03:01 ET | 10000 | 0.2 |
| 03:57 ET | 1500 | 0.2 |
| 04:00 ET | 9500 | 0.18 |
Nov 5, 2024
BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection, from 8:32AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:32AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioMark Diagnostics Inc | 16.4M | -9.6x | --- |
BetterLife Pharma Inc | 15.5M | -2.9x | --- |
Biovaxys Technology Corp | 18.3M | -2.4x | --- |
Quantum BioPharma Ltd | 13.7M | -0.3x | --- |
Sirona Biochem Corp | 19.7M | -7.2x | --- |
Resverlogix Corp | 15.3M | -0.9x | --- |
Company Information
BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.
Contact Information
- Headquarters
- 130 3851 Shell RoadRICHMOND, BC, Canada V6X 2W2
- Phone
- 604-836-6950
- Fax
- 604-836-6950
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.4M |
|---|---|
Revenue (TTM) | $161.8K |
Shares Outstanding | 90.9M |
BioMark Diagnostics Inc does not pay a dividend. | |
Beta | -0.43 |
EPS | $-0.02 |
Book Value | $-0.01 |
P/E Ratio | -9.6x |
Price/Sales (TTM) | 101.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,099.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
